GSK has agreed to acquire Nuvalent, a Boston‑based clinical‑stage oncology company, for $10.6 billion in cash, in its largest deal in more than a decade.
The deal values Nuvalent at $124 per share, a 40% premium to its last closing price of $88.49.
GSK will launch a tender offer within 10 business days to acquire all outstanding shares of Nuvalent on the Nasdaq (ticker:
NUVL).
The transaction is structured to close in Q3 2026, subject to regulatory and customary closing conditions.
GSK will pay an aggregate equity value of $10.6 billion ($9.4 billion net of cash), funded primarily through debt and existing cash.
Sources:
GSK) plans $10.6B Nuvalent acquisition to expand in lung cancer
LONDON BRIEFING: GSK agrees to buy US cancer drug maker ...
NUVL Jumps As GSK Takeover Talks And FDA Wins Ignite ...
GSK to buy US lung cancer drug specialist Nuvalent for £8bn
GSK to Acquire Nuvalent for $10.6 Billion in Lung Cancer ...
[PDF] Stock-exchange announcement - GSK
GSK pays $10.6B for cancer biotech Nuvalent in industry's ...
GSK enters agreement to acquire Nuvalent, Inc.
[PDF] Agreement to acquire Nuvalent - GSK
GSK bets $10.6bn on lung cancer future with Nuvalent buy
GSK inks $10.6B Nuvalent buyout to challenge Roche and ...
GSK to acquire Nuvalent for $10.6 billion - chemXplore
GSK to Acquire Nuvalent for $10.6 Billion to Expand Lung ...
GSK to buy cancer drug developer Nuvalent for $10.6 billion
GSK to Buy Nuvalent for $10.6 Billion in Oncology Push - Morningstar